A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin
Unknown status
Clalit Health Services
Phase 3
2008-06-01
Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of
this drug and additional drug (Janufer), In the community setting.
A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin
Unknown status
Meir Medical Center
Phase 3
2008-06-01
Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of
this drug and additional drug (Janufer), In the community setting.
Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
Completed
Merck Sharp & Dohme Corp.
Phase 4
2010-05-04
This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®),
MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary
hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior
reduction in HbA1c (mean change from baseline) compared to glimepiride.
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
Completed
Merck Sharp & Dohme Corp.
2009-03-01
This survey is conducted for preparing application materials for re-examination under the
Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the
clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and
efficacy information according to the Re-examination Regulation for New Drugs.
This preview shows a limited data set Subscribe for full access, or try a Trial
Janumet: Clinical Trials Update, Market Analysis, and Future Projections
Last updated: January 26, 2026
Summary
Janumet, a combination of sitagliptin and metformin, is used for managing type 2 diabetes mellitus. This report covers recent clinical trial developments, evaluates the current and projected market landscape, and offers strategic insights into the drug’s commercial outlook.
Clinical Trials Update for Janumet
Parameter
Details
Sources
Latest Trials
Ongoing trials evaluate Janumet's efficacy in specific populations, including elderly patients and those with comorbidities (NCT04451221, NCT03944841).
Trials investigating Janumet for prediabetes and cardiovascular outcomes are underway, expanding its therapeutic scope.
As per recent trial registrations (2022–2023).
Safety Data
Large-scale Phase IV data confirm safety profile consistent with previous findings; rare adverse effects include gastrointestinal disturbances and rare pancreatitis cases.
Published post-marketing surveillance reports (2021–2023).
Biomarker and Pharmacogenomic Studies
Research analyzing patient-specific responses aims to optimize personalized treatment strategies.
Published in Diabetes Care, 2022.
Clinical Trial Highlights and Impacts
Cardiovascular Outcomes:
The DECLARE-TIMI 58 trial demonstrated sitagliptin (component of Janumet) did not significantly reduce major adverse cardiovascular events (MACE) but was associated with a neutral risk profile, reinforcing safety in patients with high cardiovascular risk.
Efficacy in Special Populations:
Trials in elderly patients indicate comparable glycemic control with manageable safety risks, vital for extending indications in aging populations.
Novel Combinatorial Approaches:
Studies combining Janumet with SGLT2 inhibitors aim to enhance glycemic management and address weight and cardiovascular risks.
Market Analysis of Janumet
Market Segment
Details
Market Size (2022)
Growth Rate (CAGR, 2023–2028)
Sources
Global Diabetes Management Market
USD 83 billion (2022); expected to grow to USD 122 billion by 2028.
Dominated by metformin, sitagliptin, and combination drugs like Janumet.
USD 24 billion (2022)
~8%
IQVIA, 2022 Data
Janumet’s Share
Estimated at 12-15% of DPP-4 inhibitor market; strong prescriber preference in North America and Europe.
—
—
IQVIA MAT Q4 2022
Competitive Landscape
Drug
Type
Approval Year
Market Share (2022)
Key Competitors
Notes
Janumet
DPP-4 inhibitor + Metformin
2007
12-15%
Tradjenta + Metformin, Onglyza + Metformin
Established, high adherence
Dapagliflozin (Farxiga)
SGLT2 inhibitor
2014
—
Jardiance + Metformin
Growing due to CV benefits
Liraglutide (Victoza)
GLP-1 receptor agonist
2010
—
Trulicity
Market expansion influencing oral drugs
Market Trends and Drivers
Growing prevalence of type 2 diabetes: projected to reach 700 million globally by 2045 (IDF, 2021).
Shift towards combination therapies: to improve adherence and outcomes.
Regulatory environment: favoring drugs with proven cardiovascular safety (FDA, EMA).
Patient demand for oral formulations: for ease of use compared to injectables.
Future Market Projections (2023–2028)
Parameter
Projection
Details
Source
Market Growth
CAGR of 7–8%
Driven by increased diabetes prevalence and combination therapy adoption.
IQVIA, 2022
Market Penetration
20–25% of DPP-4 inhibitor market by 2028
Increased acceptance post-convincing safety and efficacy data.
Industry forecasts
Emerging Indications
Pre-diabetes and cardiovascular protection
Expected to contribute 10–15% incremental growth.
Ongoing trial results
Key Factors Influencing Future Demand
Regulatory approvals of expanded indications.
Advancements in personalized medicine integrating pharmacogenomics.
Competitive pressures from novel agents like GLP-1 RA and SGLT2 inhibitors.
Pricing and reimbursement policies in key markets such as the U.S. and EU.
Comparison with Competing Drugs
Characteristic
Janumet
Tradjenta (linagliptin + metformin)
Jardiance + metformin
Victoza (liraglutide)
Administration
Oral (tablet)
Oral (tablet)
Oral (tablet) + injection
Injection (pen)
Approved Indications
T2DM
T2DM
T2DM, CV benefits
T2DM, weight management
Market Share (2022)
12-15%
~10%
Growing rapidly
Large, but injectables
Key Advantage
Proven safety, dual mechanism
Convenience, safety
Cardiovascular benefits
Weight reduction, CV benefits
Regulatory and Policy Environment
FDA (2021–2023): Emphasizes safety profiling and cardiovascular outcome trials for antidiabetics.
EMA: Approves indications based on trial data emphasizing safety and efficacy.
Reimbursement Policies: Increasing coverage for combination agents in developed markets, with ongoing debates around cost-effectiveness.
FAQs
What are the primary clinical benefits of Janumet?
Janumet offers effective glycemic control through dual mechanisms—sitagliptin's incretin enhancement and metformin's insulin sensitivity—showing improved HbA1c reduction and weight neutrality.
Are there notable safety concerns with Janumet?
The safety profile is well-established; rare adverse events include gastrointestinal reactions and, very rarely, pancreatitis. Use with caution in patients with renal impairment.
How is Janumet positioned relative to other DPP-4 inhibitors?
Janumet, as a fixed-dose combination, improves adherence and convenience, maintaining a leading market share within DPP-4 class drugs.
What are the prospects for expanding Janumet’s indications?
Trials exploring cardiovascular benefits and prediabetic use suggest potential for label expansion, contingent on positive trial outcomes.
How will market competition from SGLT2 and GLP-1 receptor agonists impact Janumet?
Increased adoption of innovative classes offering cardiovascular and weight-loss benefits may challenge Janumet’s dominance but also open avenues for combination strategies.
Key Takeaways
Recent clinical trials reinforce Janumet’s safety and efficacy profile, while ongoing research explores expanded indications.
Market dynamics are shaped by the rising prevalence of T2DM, regulatory policies favoring cardiovascular safety, and increasing adoption of combination therapies.
Growth projections estimate a CAGR of 7–8% from 2023–2028, driven by demographic trends and continuous clinical validation.
Competitive landscape emphasizes the need for Janumet to adapt via innovation, including exploring adjunct therapies or personalized medicine approaches.
[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.
[2] IQVIA. (2022). Global Use of Medicines in Diabetes Management.
[3] ClinicalTrials.gov. (2022–2023). Ongoing Trials for Janumet and Related Indications.
[4] MarketWatch. (2022). Diabetes Management Market Size and Trends.
[5] Diabetes Care. (2022). Pharmacogenomics and Personalized Treatment for T2DM.
[6] U.S. Food and Drug Administration (FDA). (2021–2023). Diabetes Drugs Safety Updates.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
